Two stocks in Healthcare
AbbVie vs Thermo Fisher Scientific: profit, growth, debt and price compared
AbbVie is stronger on 4 of 6 figures: profit margin, sales growth, price for its expected profit and dividend. Thermo Fisher Scientific is stronger on 2: analysts' view and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AbbVieABBV | Thermo Fisher ScientificTMO | |
|---|---|---|
| Net margin | Stronger: 15.7% | 14.9% |
| Revenue growth, past year | Stronger: +10.32% | +9.13% |
| Debt to equity | — | 75.4% |
| Forward P/E | Stronger: 17.6× | 24.9× |
| Dividend yield | Stronger: 2.42% | 0.27% |
| Analysts | Buy · 26 | Stronger: Strong buy · 25 |
| From its 200-day average | +15.5% | Stronger: +17.3% |
Share price over the past year
- AbbVie+22.3%
- Thermo Fisher Scientific+20.3%
18 Nov 202518 Nov 2026
AbbVie or Thermo Fisher Scientific: which is stronger?
- ABBV
Which is more profitable?
AbbVie keeps more of each sale as profit: 15.7% against 14.9%.
- ABBV
Which is growing its sales faster?
AbbVie is growing its sales faster: +10.32% over the past year, against +9.13%.
- ABBV
Which costs less for the profit it is expected to make?
AbbVie costs less for the profit it is expected to make: 17.6× its forward earnings, against 24.9×.
- ABBV
Which pays more in dividends?
AbbVie pays more back in dividends for what a share costs: 2.42% a year, against 0.27%.
- TMO
Which do analysts rate higher?
Analysts are warmer on Thermo Fisher Scientific: Strong buy, against Buy for AbbVie.
- TMO
Which is in the stronger price trend?
Thermo Fisher Scientific's price is in the stronger trend: 17.3% above its 200-day average, against 15.5% above.
What each company does
ABBVAbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Reports results on 3 February 2027
TMOThermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.
Reports results on 28 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.